Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Hepatorenal syndrome

R Bataller1, V Arroyo, P Ginès

  • 1Liver Unit, Institute Clinic of Digestive Diseases, University of Barcelona, Barcelona, Spain.

Forum (Genoa, Italy)
|June 17, 1998
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction to: The MELD Score Is Superior to the Maddrey Discriminant Function Score to Predict Short-Term Mortality in Alcohol-Associated Hepatitis: A Global Study.

The American journal of gastroenterology·2022
Same author

The MELD Score Is Superior to the Maddrey Discriminant Function Score to Predict Short-Term Mortality in Alcohol-Associated Hepatitis: A Global Study.

The American journal of gastroenterology·2021
Same author

Neutrophil gelatinase-associated lipocalin is a biomarker of acute-on-chronic liver failure and prognosis in cirrhosis.

Journal of hepatology·2016
Same author

SPARC (secreted protein acidic and rich in cysteine) knockdown protects mice from acute liver injury by reducing vascular endothelial cell damage.

Gene therapy·2014
Same author

Distinct phenotype of hepatotoxicity associated with illicit use of anabolic androgenic steroids.

Alimentary pharmacology & therapeutics·2014
Same author

[2011: a key year in Gastroenterologia y Hepatología].

Gastroenterologia y hepatologia·2011
Same journal

The basis of allograft acceptance.

Forum (Genoa, Italy)·2011
Same journal

Recurrent liver disease after liver transplantation.

Forum (Genoa, Italy)·2011
Same journal

Integrated treatments for non-small cell lung cancer.

Forum (Genoa, Italy)·2006
Same journal

Gastrointestinal tumors.

Forum (Genoa, Italy)·2006
Same journal

Primary and metastatic brain tumors.

Forum (Genoa, Italy)·2006
Same journal

Impact of integrated treatments on patient management in solid tumors: from diagnosis to palliative care.

Forum (Genoa, Italy)·2006
See all related articles

Hepatorenal syndrome, a severe complication of cirrhosis, causes kidney failure due to altered hemodynamics. While liver transplantation is the only cure, new therapies show promise but require further study.

Area of Science:

  • Hepatology
  • Nephrology
  • Cardiovascular Physiology

Background:

  • Hepatorenal syndrome (HRS) is a critical complication in advanced cirrhosis with ascites.
  • It involves renal failure and significant systemic hemodynamic changes.
  • Pathogenesis is linked to arterial hypoperfusion and splanchnic vasodilation.

Purpose of the Study:

  • To summarize the current understanding of hepatorenal syndrome.
  • To highlight revised diagnostic criteria.
  • To discuss prognosis and emerging therapeutic strategies.

Main Methods:

  • Review of existing literature on hepatorenal syndrome.
  • Analysis of proposed revised diagnostic criteria.
  • Evaluation of current and novel treatment options.

Related Experiment Videos

Main Results:

  • Hepatorenal syndrome is characterized by renal vasoconstriction and hypoperfusion.
  • Revised definitions and diagnostic criteria have been proposed.
  • Prognosis remains poor; liver transplantation is often not feasible.

Conclusions:

  • Hepatorenal syndrome is a severe complication with poor outcomes.
  • Emerging therapies like vasoconstrictors and TIPS show potential.
  • Further prospective research is essential to validate new treatments.